Same family. Different jobs.
GLP-1 and GLP-2 are both glucagon-like peptides released from the same gut cells, but their biology splits sharply once they hit their respective receptors. GLP-1 controls blood sugar and appetite. GLP-2 rebuilds the gut lining. Confusing them costs you the right tool for the job.
Here's the plain-English version of what each peptide does, where they overlap, and which is right for which goal.
🔑 Key Takeaways
- GLP-1 acts on the brain, pancreas, and stomach to regulate appetite and blood sugar. It's the weight-loss peptide.
- GLP-2 acts on the intestinal lining to promote gut healing and barrier integrity. It's the gut-repair peptide.
- Both are co-released from L-cells after meals, but they bind different receptors and produce different effects.
- For weight loss, you want GLP-1 receptor agonists (semaglutide, tirzepatide). For short bowel syndrome or leaky gut, GLP-2 analogs (teduglutide).
- They aren't interchangeable. Using GLP-2 for weight loss won't work, and using GLP-1 for gut repair is a side benefit at best.
The shared origin
Both peptides come from a single precursor protein called proglucagon, made in your gut's L-cells (and also in the pancreas and brain). When you eat, L-cells cleave proglucagon into multiple peptides at once: GLP-1, GLP-2, glicentin, and oxyntomodulin. They're released together, but each goes off to do its own job.
What GLP-1 does
- Slows gastric emptying: food sits in your stomach longer, you feel full longer.
- Suppresses appetite via the hypothalamus: reduces "food noise" and meal size.
- Stimulates insulin release from the pancreas: only when blood sugar is high (glucose-dependent), so it doesn't cause hypoglycemia on its own.
- Suppresses glucagon: further stabilizing blood sugar.
- Cardiovascular benefits: reduces blood pressure, improves vascular function (proven in SELECT trial).
This is the peptide behind every blockbuster weight-loss drug: semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), liraglutide (Saxenda, Victoza), and the investigational retatrutide.
What GLP-2 does
- Stimulates intestinal cell growth: rebuilds the absorptive surface of your gut.
- Strengthens the gut barrier: reduces "leaky gut" by tightening the junctions between cells.
- Improves nutrient absorption: particularly important for short bowel syndrome patients.
- Reduces gut inflammation: by enhancing barrier integrity and immune signaling.
- Promotes blood flow to the intestines.
The pharmaceutical version is teduglutide (Gattex), an FDA-approved GLP-2 analog used for short bowel syndrome. There are no GLP-2 weight-loss drugs because GLP-2 doesn't suppress appetite or affect blood sugar in the way GLP-1 does.
Side-by-side comparison
| Feature | GLP-1 | GLP-2 |
|---|---|---|
| Receptor | GLP-1R (brain, pancreas, stomach, heart) | GLP-2R (intestinal cells) |
| Appetite effect | Strong suppression | None directly |
| Blood sugar | Lowers post-meal glucose | No direct effect |
| Gut barrier | Mild benefit (indirect) | Major repair effect |
| Weight loss use | Yes (15-20%) | No |
| FDA-approved drugs | Semaglutide, tirzepatide, liraglutide, dulaglutide, exenatide | Teduglutide |
| Half-life (native peptide) | ~2 minutes | ~7 minutes |
| Half-life (drug analog) | ~7 days (semaglutide) | ~2 hours (teduglutide) |
Where they overlap
Both peptides are co-released after meals, so eating a high-fiber, high-protein meal raises both. Some research suggests GLP-1 medications produce mild GLP-2-like gut benefits indirectly, but it's a side effect, not a primary use case. People with both metabolic and gut concerns sometimes pursue GLP-1 medications and accept the modest gut benefits as a bonus.
What about GLP-3?
"GLP-3" isn't a real human peptide. The term gets thrown around in marketing for retatrutide (because it's a triple agonist hitting GLP-1, GIP, and glucagon receptors), but that's not GLP-3 in the biochemical sense. There are only two glucagon-like peptides in human biology: GLP-1 and GLP-2.
Which one do you want?
- For weight loss: GLP-1 receptor agonists (semaglutide, tirzepatide).
- For type 2 diabetes: GLP-1 receptor agonists.
- For short bowel syndrome: GLP-2 analog (teduglutide).
- For Crohn's, IBD, or leaky gut: GLP-2 has more direct evidence; talk to a gastroenterologist.
- For gut healing alongside weight loss: a GLP-1 medication plus diet and lifestyle work.
If you're ready for the prescription route: MEDVi or Yucca
Two telehealth providers cover the full pipeline in 2026. Both ship from US pharmacies. Both review your file with a US-licensed clinician. Both turn around in 24 to 72 hours.
MEDVi: brand and compounded, broadest formulary
Prescribes Wegovy, Zepbound, compounded semaglutide, and compounded tirzepatide. Dietician visits and 24/7 portal support are bundled. From around $199/mo on compounded.
Signup in 4 steps: open the MEDVi intake, complete the 15-minute medical history, upload your ID, and wait for the clinician to message you. Approval lands within 24 to 72 hours. First shipment arrives in 3 to 5 days, cold-packed from a US pharmacy.
Yucca Health: lowest cash price on compounded
Compounded semaglutide from $146/mo and compounded tirzepatide from $258/mo on the 6-month plan. No membership fees, no consultation charge.
Signup in 4 steps: open the Yucca eligibility quiz, pick semaglutide or tirzepatide on a 1, 3, or 6-month plan, verify ID with a license photo, and a board-certified physician reviews. Most weekday morning submissions are approved same-day. Pharmacy ships in 2 to 4 days.
Full breakdown of every step, costs, and red flags is in the telehealth GLP-1 guide.
Frequently Asked Questions
Medical Disclaimer: This article is for informational purposes only and is not medical advice. GLP-1 medications including semaglutide and tirzepatide are prescription drugs that require evaluation by a licensed clinician. Always disclose your full medical history during intake, follow your prescribing clinician's titration schedule, and seek in-person care for severe side effects including persistent abdominal pain, signs of pancreatitis, or allergic reactions. Compounded GLP-1 medications are dispensed under FDA 503A and 503B oversight but are not FDA-approved finished products.
